Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Provexis ( (GB:PXS) ) has shared an update.
Provexis PLC reports a 103% increase in revenue for the six months ending September 2024, driven by strong sales of its Fruitflow II SD ingredient and the launch of its Irish subsidiary. The company continues to strengthen its market position through a strategic partnership with dsm-firmenich and is poised for expansion in the Chinese market with BYHEALTH, pending regulatory approvals for Fruitflow’s health claims. These developments, alongside new share issues and a robust intellectual property portfolio, are set to boost Provexis’s future commercial prospects and operational capabilities.
More about Provexis
Provexis PLC operates in the functional food ingredient industry, focusing on the development, licensing, and sale of scientifically-proven heart-health products, notably Fruitflow®. The company is expanding its market presence through a new subsidiary in the EU and a long-term partnership with dsm-firmenich, aiming to enhance its global footprint and engage in significant commercial projects.
YTD Price Performance: 3.85%
Average Trading Volume: 503,825
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £15.83M
For detailed information about PXS stock, go to TipRanks’ Stock Analysis page.
